https://doi.org/10.4081/monaldi.2021.1721
Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target
Submitted: December 5, 2020
Accepted: January 8, 2021
Published: May 4, 2021
Accepted: January 8, 2021
Abstract Views: 1118
PDF: 637
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To the Editor
COVID-19 (COrona VIrus Disease) patients with cardiovascular (CV) disease, multiple CV risk factors or comorbidities (i.e., arterial hypertension and diabetes) were shown to be more prone to a worse prognosis. SARS-CoV-2 is a still unknown enemy and the role of concomitant cardiovascular therapies has been controversial in the early stages, particularly with regard to Angiotensin-Converting Enzyme inhibitors...
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42.
DOI: https://doi.org/10.1001/jama.2020.2648
Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013;99:417–35.
DOI: https://doi.org/10.1016/j.antiviral.2013.06.018
Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12.
DOI: https://doi.org/10.1378/chest.06-1997
Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011;342:d1642.
DOI: https://doi.org/10.1136/bmj.d1642
Shrivastava-Ranjan P, Flint M, Bergeron É, et al. Statins suppress Ebola virus infectivity by interfering with glycoprotein processing. mBio 2018;9:e00660-18.
DOI: https://doi.org/10.1128/mBio.00660-18
Yuan S. Statins may decrease the fatality rate of middle east respiratory syndrome infection. mBio 2015;6:e01120.
DOI: https://doi.org/10.1128/mBio.01120-15
Gupta A, Madhavan M V, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Res Sq 2020; rs.3.rs-56210. Preprint
DOI: https://doi.org/10.21203/rs.3.rs-56210/v1
Fan Y, Guo T, Yan F, et al. Association of statin use with the in-hospital outcomes of 2019-coronavirus disease patients: A retrospective study. Front Med (Lausanne) 2020;7:584870.
DOI: https://doi.org/10.3389/fmed.2020.584870
Zhang X-J, Qin J-J, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 2020;32:176-87.e4.
DOI: https://doi.org/10.1016/j.cmet.2020.06.015
Saeed O, Castagna F, Agalliu I, et al. Statin use and inâ€hospital mortality in diabetics with COVIDâ€19. J Am Heart Assoc 2020;9:e018475.
DOI: https://doi.org/10.1161/JAHA.120.018475
Song SL, Hays SB, Panton CE, et al. Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: A preliminary study. Pathogens 2020;9:759.
DOI: https://doi.org/10.3390/pathogens9090759
Daniels LB, Sitapati AM, Zhang J, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol 2020;136:149-55.
DOI: https://doi.org/10.1016/j.amjcard.2020.09.012
Butt JH, Gerds TA, Schou M, et al. Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ Open 2020;10:e044421.
DOI: https://doi.org/10.1136/bmjopen-2020-044421
Cariou B, Goronflot T, Rimbert A, et al. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes Metab 202;101202.
DOI: https://doi.org/10.1016/j.diabet.2020.10.001
Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol 2020;134:153–5.
DOI: https://doi.org/10.1016/j.amjcard.2020.08.004
Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr Clin Res Rev 2020;14:1613–5.
DOI: https://doi.org/10.1016/j.dsx.2020.08.023
Scheen AJ. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. Diabetes Metab 2020;47:101220.
DOI: https://doi.org/10.1016/j.diabet.2020.101220
Bikdeli B, Talasaz AH, Rashidi F, et al. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thromb Res 2020;196:382–94.
DOI: https://doi.org/10.1016/j.thromres.2020.09.027
Cesaro A, Bianconi V, Gragnano F, et al. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for longâ€term inhibition. Biofactors 2020;46:367-80.
DOI: https://doi.org/10.1002/biof.1619
Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis 2020;313:126-36.
DOI: https://doi.org/10.1016/j.atherosclerosis.2020.09.008
Mureddu GF, Ambrosetti M, Venturini E, et al. Cardiac rehabilitation activities during the COVID-19 pandemic in Italy. Position Paper of the AICPR (Italian Association of Clinical Cardiology, Prevention and Rehabilitation). Monaldi Arch Chest Dis 2020;90:1439.
DOI: https://doi.org/10.4081/monaldi.2020.1439
Gragnano F, Natale F, Concilio C, et al. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: An Italian single-center experience. J Cardiovasc Med 2018;19:75–7.
DOI: https://doi.org/10.2459/JCM.0000000000000611
Cesaro A, Gragnano F, Fimiani F, et al. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. Eur J Prev Cardiol 2020;27:556-8.
DOI: https://doi.org/10.1177/2047487319839179
Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 2019;26:824-35.
DOI: https://doi.org/10.1177/2047487318825350
How to Cite
Cesaro, Arturo, Carmine Riccio, and Paolo Calabrò. 2021. “Lipid-Lowering Therapy in High Cardiovascular Risk Patients During COVID-19 Pandemic: Keep Focused on the Target”. Monaldi Archives for Chest Disease 91 (2). https://doi.org/10.4081/monaldi.2021.1721.
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Angelica Cersosimo, Mattia Di Pasquale, Gianmarco Arabia, Marco Metra, Enrico Vizzardi, COVID myocarditis: a review of the literature , Monaldi Archives for Chest Disease: Early Access
- Gianluigi Balestroni, Giovanna Omarini, Pierangela Omarini, Massimo Pistono, Ugo Corrà , Marco Gnemmi, Pantaleo Giannuzzi, Left ventricular assist device: which emotional impact on the patient? , Monaldi Archives for Chest Disease: Vol. 82 No. 2 (2014): Cardiac series
- Francesco Fattirolli, Position ANDID on: The role of Dietitian in cardiac rehabilitation and prevention. A comment , Monaldi Archives for Chest Disease: Vol. 70 No. 3 (2008): Cardiac series
- Salvatore Pirelli, The program of Italian Working Group on Cardiac Rehabilitation and Prevention for the period 2004-2005 , Monaldi Archives for Chest Disease: Vol. 64 No. 1 (2005): Cardiac series
- Francesco Fattirolli, Considerations on Cardiac Rehabilitation: the paradigm of complexity , Monaldi Archives for Chest Disease: Vol. 82 No. 3 (2014): Cardiac series
- Giuseppina Majani, Psychology in Cardiac Rehabilitation: where all problems emerge and should be solved , Monaldi Archives for Chest Disease: Vol. 78 No. 2 (2012): Cardiac series
- Riccardo Raddino, Ivano Bonadei, Melissa Teli, Federica Chieppa, Giorgio Caretta, Debora Robba, Gregoriana Zanini, Enrico Vizzardi, Livio Dei Cas, Peripartum Cardiomyopathy , Monaldi Archives for Chest Disease: Vol. 70 No. 1 (2008): Cardiac series
- Massimo F. Piepoli, Exercise Rehabilitation in Heart Disease: the real “polypill†for primary and secondary prevention , Monaldi Archives for Chest Disease: Vol. 64 No. 2 (2005): Cardiac series
- Carmine Riccio, Marinella Sommaruga, Paola Vaghi, Alfonso Cassella, Silvana Celardo, Emilia Cocco, Vincenzo de Chiro, Maria Marzaioli, Enza Ruotolo, Ornella Zanni, Maria Iacomino, Carmelo Chieffo, Nursing Role in Cardiac Prevention , Monaldi Archives for Chest Disease: Vol. 62 No. 2 (2004): Cardiac series
- P.M. RodrÃguez Suárez, J.L. Freixinet Gilart, Pleurodesis in the treatment of pneumothorax and pleural effusion , Monaldi Archives for Chest Disease: Vol. 79 No. 2 (2013): Pulmonary series
<< < 25 26 27 28 29 30 31 32 33 34 > >>
You may also start an advanced similarity search for this article.
